{
  "ticker": "BBIO",
  "company_name": "BridgeBio Pharma, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05375084",
      "title": "SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Non Small Cell Lung Cancer, Solid Tumor",
      "start_date": "2022-10-20",
      "completion_date": "2024-07-15",
      "enrollment": 0,
      "sponsor": "Navire Pharma Inc., a BridgeBio company"
    },
    {
      "nct_id": "NCT07062848",
      "title": "An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "",
      "condition": "Transthyretin (TTR) Amyloid Cardiomyopathy",
      "start_date": "2025-01-24",
      "completion_date": "2027-01",
      "enrollment": 0,
      "sponsor": "Yale University"
    },
    {
      "nct_id": "NCT05480865",
      "title": "SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer",
      "start_date": "2022-07-06",
      "completion_date": "2024-08-22",
      "enrollment": 0,
      "sponsor": "Navire Pharma Inc., a BridgeBio company"
    },
    {
      "nct_id": "NCT04528836",
      "title": "First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Tumor, Solid",
      "start_date": "2020-11-12",
      "completion_date": "2024-07-30",
      "enrollment": 0,
      "sponsor": "Navire Pharma Inc., a BridgeBio company"
    }
  ],
  "summary": {
    "total_trials": 4,
    "by_phase": {
      "PHASE1": 3,
      "": 1
    },
    "by_status": {
      "TERMINATED": 3,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 0,
    "conditions": [
      "Non Small Cell Lung Cancer, Solid Tumor",
      "Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer",
      "Transthyretin (TTR) Amyloid Cardiomyopathy",
      "Tumor, Solid"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:33:11.226911",
    "search_query": "BridgeBio Pharma, Inc.",
    "url": "https://clinicaltrials.gov/search?term=BridgeBio+Pharma,+Inc."
  }
}